Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.46 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | PKLR | P30613 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 4/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25525962 | 0.84 | TAAR1 (0.50) | SIGMAR1GRIN2BMEN1KMT2AL3MBTL1 | |
| SCHEMBL20147389 | 0.83 | LMNA (0.51) | SIGMAR1GRIN2BMEN1KMT2AL3MBTL1 | |
| SCHEMBL5343612 | 0.80 | MEN1 (0.50) | SIGMAR1GRIN2BMEN1KMT2AHRH3 | |
| SCHEMBL20069604 | 0.78 | SLC6A2 (0.49) | SIGMAR1GRIN2B | |
| SCHEMBL27597082 | 0.78 | MEN1 (0.51) | GRIN2BMEN1KMT2AL3MBTL1PKLR | |
| Hydrochloric Acid SCHEMBL20138442 | 0.77 | SLC6A2 (0.48) | GRIN2B | |
| SCHEMBL20137883 | 0.76 | ROCK2 (0.49) | GRIN2BMEN1KMT2AL3MBTL1PKLR | |
| SCHEMBL3163183 | 0.69 | TAAR1 (0.54) | SIGMAR1HRH3 | |
| Hydrochloric Acid SCHEMBL7842582 | 0.69 | SLC6A2 (0.51) | PKLRALDH1A1 | |
| SCHEMBL30601824 | 0.68 | L3MBTL1 (0.57) | MEN1KMT2AL3MBTL1ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10441581-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2019-10-15 | — | — | US | disclosed |
| US-20180133207-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10441581-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | RET, BRAF, RAF1 | SIGMAR1 3807/4885GRIN2B 1206/4885MEN1 653/4885 |
| US-20180133207-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, BRAF, RAF1 | SIGMAR1 3807/4885GRIN2B 1206/4885MEN1 653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.